文献速递基础与转化研究临床试验与 GCP

瘤内释药微装置可在胶质瘤患者中实现原位高通量药物表型分析

Intratumoral drug-releasing microdevices allow in situ high-throughput pharmaco phenotyping in patients with gliomas.
PubMed 文献 · Sci Transl Med · 2023-09-06

该首次人体试点临床试验(NCT04135807)评估瘤内释药微装置(IMD)在高级别胶质瘤手术中获取患者特异性高通量分子与组织病理学药物反应谱的安全性和可行性。6例入组患者均未发生与IMD相关的不良事件,12份回收标本中11份可用于下游分析,分析结果初步显示读出稳健、兼容多种分子检测技术,并与替莫唑胺的临床-影像学反应具有相似性。

要点

  • 瘤内释药微装置可在标准手术2至3小时内安全置入并原位维持,6例患者均无相关不良事件。
  • 12份回收标本中11份可用于下游分析,读出初步显示稳健且兼容多种分子组织检测技术。
  • 标本分析结果与替莫唑胺的临床-影像学反应具有相似性,可补充药物选择策略。

核心结论

  • 首次人体证据表明,瘤内释药微装置可安全有效地获取患者特异性高通量分子与组织病理学药物反应谱。
  • 这些数据可补充其他策略,以根据药物在原位的抗肿瘤效应指导药物选择。

研究设计与样本

  • 试点临床试验(NCT04135807),首次人体研究,入组6例高级别胶质瘤患者。
  • IMD在肿瘤切除手术中整合使用,仅在标准手术期间(2至3小时)原位留置。

主要发现

  • 6例入组患者均未发生与IMD相关的不良事件。
  • 12份回收标本中11份可用于下游分析。
  • 标本分析初步显示读出稳健,兼容多种分子组织检测技术,并与替莫唑胺的临床-影像学反应具有相似性。

临床怎么用

  • IMD可整合于肿瘤切除手术中,仅在标准手术期间(2至3小时)原位留置,不影响标准手术流程。
  • 从研究角度,IMD获取的信息可在完整肿瘤的生理背景下表征任何感兴趣药物的组织效应。

局限性

  • 原文未报告局限性

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

The lack of reliable predictive biomarkers to guide effective therapy is a major obstacle to the advancement of therapy for high-grade gliomas, particularly glioblastoma (GBM), one of the few cancers whose prognosis has not improved over the past several decades. With this pilot clinical trial (number NCT04135807), we provide first-in-human evidence that drug-releasing intratumoral microdevices (IMDs) can be safely and effectively used to obtain patient-specific, high-throughput molecular and histopathological drug response profiling. These data can complement other strategies to inform the selection of drugs based on their observed antitumor effect in situ. IMDs are integrated into surgical practice during tumor resection and remain in situ only for the duration of the otherwise standard operation (2 to 3 hours). None of the six enrolled patients experienced adverse events related to the IMD, and the exposed tissue was usable for downstream analysis for 11 out of 12 retrieved specimens. Analysis of the specimens provided preliminary evidence of the robustness of the readout, compatibility with a wide array of techniques for molecular tissue interrogation, and promising similarities with the available observed clinical-radiological responses to temozolomide. From an investigational aspect, the amount of information obtained with IMDs allows characterization of tissue effects of any drugs of interest, within the physiological context of the intact tumor, and without affecting the standard surgical workflow.

来源:Sci Transl Med,查看原文。版权归原作者所有。

引用

  1. Peruzzi P, Dominas C, Fell G, et al. Intratumoral drug-releasing microdevices allow in situ high-throughput pharmaco phenotyping in patients with gliomas. Sci Transl Med. 2023. PMID: 37672566. doi:10.1126/scitranslmed.adi0069

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。